Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 58

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 58
---
’ equity is translated using historical rates. Foreign exchange transaction gains and losses are included in other income/expense in the Company’s results of operations and comprehensive loss. Research and Development Costs for research and development, or R&D of products, including vendor expenses and supplies and consultant fees, are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the obligations are recorded when the milestone results are probable of being achieved. Fair Value Measurements The Company measures and discloses fair value in accordance with ASC 820, “ Fair Value,”which defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market -basedmeasurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Annex A-9 NLS PHARMACEUTICS LTD.
NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

As a basis for considering such assumptions there exists a three -tierfair -valuehierarchy, which prioritizes the inputs used in measuring fair value as follows:

| Level 1 — |     | unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.                                                                                                                                                                                                                                                                                                                             |
| Level 2 — |     | pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.                                                                                                                                                                                                                                                                                               |
| Level 3 — |     | pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors. |

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company’s cash and cash equivalents are carried at fair value, determined according to the fair value